

Global Renin-Angiotensin-System (RAS)-Acting Agent Market Growth 2026-2032

<https://marketpublishers.com/r/G5876E99CAE5EN.html>

Date: April 2026

Pages: 102

Price: US\$ 3,660.00 (Single User License)

ID: G5876E99CAE5EN

Abstracts

The global Renin-Angiotensin-System (RAS)-Acting Agent market size is predicted to grow from US\$ million in 2025 to US\$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.

According to our research, the global market for medical devices is estimated at US\$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.

LP Information, Inc. (LPI) ' newest research report, the "Renin-Angiotensin-System (RAS)-Acting Agent Industry Forecast" looks at past sales and reviews total world Renin-Angiotensin-System (RAS)-Acting Agent sales in 2025, providing a comprehensive analysis by region and market sector of projected Renin-Angiotensin-System (RAS)-Acting Agent sales for 2026 through 2032. With Renin-Angiotensin-System (RAS)-Acting Agent sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Renin-Angiotensin-System (RAS)-Acting Agent industry.

This Insight Report provides a comprehensive analysis of the global Renin-Angiotensin-System (RAS)-Acting Agent landscape and highlights key trends related to product

segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Renin-Angiotensin-System (RAS)-Acting Agent portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Renin-Angiotensin-System (RAS)-Acting Agent market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Renin-Angiotensin-System (RAS)-Acting Agent and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Renin-Angiotensin-System (RAS)-Acting Agent.

This report presents a comprehensive overview, market shares, and growth opportunities of Renin-Angiotensin-System (RAS)-Acting Agent market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

Angiotensin Converting Enzyme Inhibitors (ACEi)

Angiotensin Receptor Blockers (ARBs)

Segmentation by Application:

Hypertension

Heart Failure

Chronic Kidney Disease

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Novartis AG

Pfizer, Inc.

AstraZeneca plc

Merck & Co., Inc.

Sanofi S.A.

Bristol-Myers Squibb Company

Daiichi Sankyo Company, Limited

Takeda Pharmaceutical Company Limited

Boehringer Ingelheim GmbH

Johnson & Johnson

Key Questions Addressed in this Report

What is the 10-year outlook for the global Renin-Angiotensin-System (RAS)-Acting Agent market?

What factors are driving Renin-Angiotensin-System (RAS)-Acting Agent market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Renin-Angiotensin-System (RAS)-Acting Agent market opportunities vary by end market size?

How does Renin-Angiotensin-System (RAS)-Acting Agent break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

- 2.1.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Annual Sales 2021-2032
- 2.1.2 World Current & Future Analysis for Renin-Angiotensin-System (RAS)-Acting Agent by Geographic Region, 2021, 2025 & 2032
- 2.1.3 World Current & Future Analysis for Renin-Angiotensin-System (RAS)-Acting Agent by Country/Region, 2021, 2025 & 2032

2.2 Renin-Angiotensin-System (RAS)-Acting Agent Segment by Type

- 2.2.1 Angiotensin Converting Enzyme Inhibitors (ACEi)
- 2.2.2 Angiotensin Receptor Blockers (ARBs)
- 2.2.3 Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type
 - 2.2.3.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Type (2021-2026)
 - 2.2.3.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue and Market Share by Type (2021-2026)
 - 2.2.3.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Sale Price by Type (2021-2026)

2.3 Renin-Angiotensin-System (RAS)-Acting Agent Segment by Application

- 2.3.1 Hypertension
- 2.3.2 Heart Failure
- 2.3.3 Chronic Kidney Disease
- 2.3.4 Other
- 2.3.5 Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application
 - 2.3.5.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Sale Market Share by Application (2021-2026)

2.3.5.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue and Market Share by Application (2021-2026)

2.3.5.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

3.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Breakdown Data by Company

3.1.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Annual Sales by Company (2021-2026)

3.1.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Company (2021-2026)

3.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Annual Revenue by Company (2021-2026)

3.2.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Company (2021-2026)

3.2.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Company (2021-2026)

3.3 Global Renin-Angiotensin-System (RAS)-Acting Agent Sale Price by Company

3.4 Key Manufacturers Renin-Angiotensin-System (RAS)-Acting Agent Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Renin-Angiotensin-System (RAS)-Acting Agent Product Location Distribution

3.4.2 Players Renin-Angiotensin-System (RAS)-Acting Agent Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR RENIN-ANGIOTENSIN-SYSTEM (RAS)-ACTING AGENT BY GEOGRAPHIC REGION

4.1 World Historic Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Geographic Region (2021-2026)

4.1.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Annual Sales by Geographic Region (2021-2026)

4.1.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Annual Revenue by

Geographic Region (2021-2026)

4.2 World Historic Renin-Angiotensin-System (RAS)-Acting Agent Market Size by Country/Region (2021-2026)

4.2.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Annual Sales by Country/Region (2021-2026)

4.2.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Annual Revenue by Country/Region (2021-2026)

4.3 Americas Renin-Angiotensin-System (RAS)-Acting Agent Sales Growth

4.4 APAC Renin-Angiotensin-System (RAS)-Acting Agent Sales Growth

4.5 Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales Growth

4.6 Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales Growth

5 AMERICAS

5.1 Americas Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country

5.1.1 Americas Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2021-2026)

5.1.2 Americas Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Country (2021-2026)

5.2 Americas Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type (2021-2026)

5.3 Americas Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application (2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Renin-Angiotensin-System (RAS)-Acting Agent Sales by Region

6.1.1 APAC Renin-Angiotensin-System (RAS)-Acting Agent Sales by Region (2021-2026)

6.1.2 APAC Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Region (2021-2026)

6.2 APAC Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type (2021-2026)

6.3 APAC Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application (2021-2026)

6.4 China

- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan

7 EUROPE

- 7.1 Europe Renin-Angiotensin-System (RAS)-Acting Agent by Country
 - 7.1.1 Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2021-2026)
 - 7.1.2 Europe Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Country (2021-2026)
- 7.2 Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type (2021-2026)
- 7.3 Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application (2021-2026)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent by Country
 - 8.1.1 Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2021-2026)
 - 8.1.2 Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Country (2021-2026)
- 8.2 Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type (2021-2026)
- 8.3 Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application (2021-2026)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Renin-Angiotensin-System (RAS)-Acting Agent

10.3 Manufacturing Process Analysis of Renin-Angiotensin-System (RAS)-Acting Agent

10.4 Industry Chain Structure of Renin-Angiotensin-System (RAS)-Acting Agent

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Renin-Angiotensin-System (RAS)-Acting Agent Distributors

11.3 Renin-Angiotensin-System (RAS)-Acting Agent Customer

12 WORLD FORECAST REVIEW FOR RENIN-ANGIOTENSIN-SYSTEM (RAS)-ACTING AGENT BY GEOGRAPHIC REGION

12.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Market Size Forecast by Region

12.1.1 Global Renin-Angiotensin-System (RAS)-Acting Agent Forecast by Region (2027-2032)

12.1.2 Global Renin-Angiotensin-System (RAS)-Acting Agent Annual Revenue Forecast by Region (2027-2032)

12.2 Americas Forecast by Country (2027-2032)

12.3 APAC Forecast by Region (2027-2032)

12.4 Europe Forecast by Country (2027-2032)

12.5 Middle East & Africa Forecast by Country (2027-2032)

12.6 Global Renin-Angiotensin-System (RAS)-Acting Agent Forecast by Type (2027-2032)

12.7 Global Renin-Angiotensin-System (RAS)-Acting Agent Forecast by Application

(2027-2032)

13 KEY PLAYERS ANALYSIS

13.1 Novartis AG

13.1.1 Novartis AG Company Information

13.1.2 Novartis AG Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolios and Specifications

13.1.3 Novartis AG Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue, Price and Gross Margin (2021-2026)

13.1.4 Novartis AG Main Business Overview

13.1.5 Novartis AG Latest Developments

13.2 Pfizer, Inc.

13.2.1 Pfizer, Inc. Company Information

13.2.2 Pfizer, Inc. Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolios and Specifications

13.2.3 Pfizer, Inc. Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue, Price and Gross Margin (2021-2026)

13.2.4 Pfizer, Inc. Main Business Overview

13.2.5 Pfizer, Inc. Latest Developments

13.3 AstraZeneca plc

13.3.1 AstraZeneca plc Company Information

13.3.2 AstraZeneca plc Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolios and Specifications

13.3.3 AstraZeneca plc Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue, Price and Gross Margin (2021-2026)

13.3.4 AstraZeneca plc Main Business Overview

13.3.5 AstraZeneca plc Latest Developments

13.4 Merck & Co., Inc.

13.4.1 Merck & Co., Inc. Company Information

13.4.2 Merck & Co., Inc. Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolios and Specifications

13.4.3 Merck & Co., Inc. Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue, Price and Gross Margin (2021-2026)

13.4.4 Merck & Co., Inc. Main Business Overview

13.4.5 Merck & Co., Inc. Latest Developments

13.5 Sanofi S.A.

13.5.1 Sanofi S.A. Company Information

13.5.2 Sanofi S.A. Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolios

and Specifications

13.5.3 Sanofi S.A. Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue, Price and Gross Margin (2021-2026)

13.5.4 Sanofi S.A. Main Business Overview

13.5.5 Sanofi S.A. Latest Developments

13.6 Bristol-Myers Squibb Company

13.6.1 Bristol-Myers Squibb Company Company Information

13.6.2 Bristol-Myers Squibb Company Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolios and Specifications

13.6.3 Bristol-Myers Squibb Company Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue, Price and Gross Margin (2021-2026)

13.6.4 Bristol-Myers Squibb Company Main Business Overview

13.6.5 Bristol-Myers Squibb Company Latest Developments

13.7 Daiichi Sankyo Company, Limited

13.7.1 Daiichi Sankyo Company, Limited Company Information

13.7.2 Daiichi Sankyo Company, Limited Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolios and Specifications

13.7.3 Daiichi Sankyo Company, Limited Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue, Price and Gross Margin (2021-2026)

13.7.4 Daiichi Sankyo Company, Limited Main Business Overview

13.7.5 Daiichi Sankyo Company, Limited Latest Developments

13.8 Takeda Pharmaceutical Company Limited

13.8.1 Takeda Pharmaceutical Company Limited Company Information

13.8.2 Takeda Pharmaceutical Company Limited Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolios and Specifications

13.8.3 Takeda Pharmaceutical Company Limited Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue, Price and Gross Margin (2021-2026)

13.8.4 Takeda Pharmaceutical Company Limited Main Business Overview

13.8.5 Takeda Pharmaceutical Company Limited Latest Developments

13.9 Boehringer Ingelheim GmbH

13.9.1 Boehringer Ingelheim GmbH Company Information

13.9.2 Boehringer Ingelheim GmbH Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolios and Specifications

13.9.3 Boehringer Ingelheim GmbH Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue, Price and Gross Margin (2021-2026)

13.9.4 Boehringer Ingelheim GmbH Main Business Overview

13.9.5 Boehringer Ingelheim GmbH Latest Developments

13.10 Johnson & Johnson

13.10.1 Johnson & Johnson Company Information

13.10.2 Johnson & Johnson Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolios and Specifications

13.10.3 Johnson & Johnson Renin-Angiotensin-System (RAS)-Acting Agent Sales, Revenue, Price and Gross Margin (2021-2026)

13.10.4 Johnson & Johnson Main Business Overview

13.10.5 Johnson & Johnson Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Renin-Angiotensin-System (RAS)-Acting Agent Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Table 2. Renin-Angiotensin-System (RAS)-Acting Agent Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of Angiotensin Converting Enzyme Inhibitors (ACEi)

Table 4. Major Players of Angiotensin Receptor Blockers (ARBs)

Table 5. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type (2021-2026) & (K Units)

Table 6. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Type (2021-2026)

Table 7. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Type (2021-2026) & (\$ million)

Table 8. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Type (2021-2026)

Table 9. Global Renin-Angiotensin-System (RAS)-Acting Agent Sale Price by Type (2021-2026) & (US\$/Unit)

Table 10. Global Renin-Angiotensin-System (RAS)-Acting Agent Sale by Application (2021-2026) & (K Units)

Table 11. Global Renin-Angiotensin-System (RAS)-Acting Agent Sale Market Share by Application (2021-2026)

Table 12. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Application (2021-2026) & (\$ million)

Table 13. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Application (2021-2026)

Table 14. Global Renin-Angiotensin-System (RAS)-Acting Agent Sale Price by Application (2021-2026) & (US\$/Unit)

Table 15. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Company (2021-2026) & (K Units)

Table 16. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Company (2021-2026)

Table 17. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Company (2021-2026) & (\$ millions)

Table 18. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Company (2021-2026)

Table 19. Global Renin-Angiotensin-System (RAS)-Acting Agent Sale Price by

Company (2021-2026) & (US\$/Unit)

Table 20. Key Manufacturers Renin-Angiotensin-System (RAS)-Acting Agent Producing Area Distribution and Sales Area

Table 21. Players Renin-Angiotensin-System (RAS)-Acting Agent Products Offered

Table 22. Renin-Angiotensin-System (RAS)-Acting Agent Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 23. New Products and Potential Entrants

Table 24. Market M&A Activity & Strategy

Table 25. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Geographic Region (2021-2026) & (K Units)

Table 26. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share Geographic Region (2021-2026)

Table 27. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Geographic Region (2021-2026) & (\$ millions)

Table 28. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Geographic Region (2021-2026)

Table 29. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country/Region (2021-2026) & (K Units)

Table 30. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Country/Region (2021-2026)

Table 31. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Country/Region (2021-2026) & (\$ millions)

Table 32. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Country/Region (2021-2026)

Table 33. Americas Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country (2021-2026) & (K Units)

Table 34. Americas Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Country (2021-2026)

Table 35. Americas Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Country (2021-2026) & (\$ millions)

Table 36. Americas Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type (2021-2026) & (K Units)

Table 37. Americas Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application (2021-2026) & (K Units)

Table 38. APAC Renin-Angiotensin-System (RAS)-Acting Agent Sales by Region (2021-2026) & (K Units)

Table 39. APAC Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Region (2021-2026)

Table 40. APAC Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Region

(2021-2026) & (\$ millions)

Table 41. APAC Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type
(2021-2026) & (K Units)

Table 42. APAC Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application
(2021-2026) & (K Units)

Table 43. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales by Country
(2021-2026) & (K Units)

Table 44. Europe Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Country
(2021-2026) & (\$ millions)

Table 45. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales by Type
(2021-2026) & (K Units)

Table 46. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales by Application
(2021-2026) & (K Units)

Table 47. Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales by
Country (2021-2026) & (K Units)

Table 48. Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Revenue
Market Share by Country (2021-2026)

Table 49. Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales by
Type (2021-2026) & (K Units)

Table 50. Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales by
Application (2021-2026) & (K Units)

Table 51. Key Market Drivers & Growth Opportunities of Renin-Angiotensin-System
(RAS)-Acting Agent

Table 52. Key Market Challenges & Risks of Renin-Angiotensin-System (RAS)-Acting
Agent

Table 53. Key Industry Trends of Renin-Angiotensin-System (RAS)-Acting Agent

Table 54. Renin-Angiotensin-System (RAS)-Acting Agent Raw Material

Table 55. Key Suppliers of Raw Materials

Table 56. Renin-Angiotensin-System (RAS)-Acting Agent Distributors List

Table 57. Renin-Angiotensin-System (RAS)-Acting Agent Customer List

Table 58. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Forecast by
Region (2027-2032) & (K Units)

Table 59. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Forecast by
Region (2027-2032) & (\$ millions)

Table 60. Americas Renin-Angiotensin-System (RAS)-Acting Agent Sales Forecast by
Country (2027-2032) & (K Units)

Table 61. Americas Renin-Angiotensin-System (RAS)-Acting Agent Annual Revenue
Forecast by Country (2027-2032) & (\$ millions)

Table 62. APAC Renin-Angiotensin-System (RAS)-Acting Agent Sales Forecast by

Region (2027-2032) & (K Units)

Table 63. APAC Renin-Angiotensin-System (RAS)-Acting Agent Annual Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 64. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales Forecast by Country (2027-2032) & (K Units)

Table 65. Europe Renin-Angiotensin-System (RAS)-Acting Agent Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 66. Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales Forecast by Country (2027-2032) & (K Units)

Table 67. Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 68. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Forecast by Type (2027-2032) & (K Units)

Table 69. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Forecast by Type (2027-2032) & (\$ millions)

Table 70. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Forecast by Application (2027-2032) & (K Units)

Table 71. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Forecast by Application (2027-2032) & (\$ millions)

Table 72. Novartis AG Basic Information, Renin-Angiotensin-System (RAS)-Acting Agent Manufacturing Base, Sales Area and Its Competitors

Table 73. Novartis AG Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolios and Specifications

Table 74. Novartis AG Renin-Angiotensin-System (RAS)-Acting Agent Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 75. Novartis AG Main Business

Table 76. Novartis AG Latest Developments

Table 77. Pfizer, Inc. Basic Information, Renin-Angiotensin-System (RAS)-Acting Agent Manufacturing Base, Sales Area and Its Competitors

Table 78. Pfizer, Inc. Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolios and Specifications

Table 79. Pfizer, Inc. Renin-Angiotensin-System (RAS)-Acting Agent Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 80. Pfizer, Inc. Main Business

Table 81. Pfizer, Inc. Latest Developments

Table 82. AstraZeneca plc Basic Information, Renin-Angiotensin-System (RAS)-Acting Agent Manufacturing Base, Sales Area and Its Competitors

Table 83. AstraZeneca plc Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolios and Specifications

Table 84. AstraZeneca plc Renin-Angiotensin-System (RAS)-Acting Agent Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 85. AstraZeneca plc Main Business

Table 86. AstraZeneca plc Latest Developments

Table 87. Merck & Co., Inc. Basic Information, Renin-Angiotensin-System (RAS)-Acting Agent Manufacturing Base, Sales Area and Its Competitors

Table 88. Merck & Co., Inc. Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolios and Specifications

Table 89. Merck & Co., Inc. Renin-Angiotensin-System (RAS)-Acting Agent Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 90. Merck & Co., Inc. Main Business

Table 91. Merck & Co., Inc. Latest Developments

Table 92. Sanofi S.A. Basic Information, Renin-Angiotensin-System (RAS)-Acting Agent Manufacturing Base, Sales Area and Its Competitors

Table 93. Sanofi S.A. Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolios and Specifications

Table 94. Sanofi S.A. Renin-Angiotensin-System (RAS)-Acting Agent Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 95. Sanofi S.A. Main Business

Table 96. Sanofi S.A. Latest Developments

Table 97. Bristol-Myers Squibb Company Basic Information, Renin-Angiotensin-System (RAS)-Acting Agent Manufacturing Base, Sales Area and Its Competitors

Table 98. Bristol-Myers Squibb Company Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolios and Specifications

Table 99. Bristol-Myers Squibb Company Renin-Angiotensin-System (RAS)-Acting Agent Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 100. Bristol-Myers Squibb Company Main Business

Table 101. Bristol-Myers Squibb Company Latest Developments

Table 102. Daiichi Sankyo Company,Limited Basic Information, Renin-Angiotensin-System (RAS)-Acting Agent Manufacturing Base, Sales Area and Its Competitors

Table 103. Daiichi Sankyo Company,Limited Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolios and Specifications

Table 104. Daiichi Sankyo Company,Limited Renin-Angiotensin-System (RAS)-Acting Agent Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 105. Daiichi Sankyo Company,Limited Main Business

Table 106. Daiichi Sankyo Company,Limited Latest Developments

Table 107. Takeda Pharmaceutical Company Limited Basic Information, Renin-

Angiotensin-System (RAS)-Acting Agent Manufacturing Base, Sales Area and Its Competitors

Table 108. Takeda Pharmaceutical Company Limited Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolios and Specifications

Table 109. Takeda Pharmaceutical Company Limited Renin-Angiotensin-System (RAS)-Acting Agent Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 110. Takeda Pharmaceutical Company Limited Main Business

Table 111. Takeda Pharmaceutical Company Limited Latest Developments

Table 112. Boehringer Ingelheim GmbH Basic Information, Renin-Angiotensin-System (RAS)-Acting Agent Manufacturing Base, Sales Area and Its Competitors

Table 113. Boehringer Ingelheim GmbH Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolios and Specifications

Table 114. Boehringer Ingelheim GmbH Renin-Angiotensin-System (RAS)-Acting Agent Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 115. Boehringer Ingelheim GmbH Main Business

Table 116. Boehringer Ingelheim GmbH Latest Developments

Table 117. Johnson & Johnson Basic Information, Renin-Angiotensin-System (RAS)-Acting Agent Manufacturing Base, Sales Area and Its Competitors

Table 118. Johnson & Johnson Renin-Angiotensin-System (RAS)-Acting Agent Product Portfolios and Specifications

Table 119. Johnson & Johnson Renin-Angiotensin-System (RAS)-Acting Agent Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 120. Johnson & Johnson Main Business

Table 121. Johnson & Johnson Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Renin-Angiotensin-System (RAS)-Acting Agent
- Figure 2. Renin-Angiotensin-System (RAS)-Acting Agent Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Growth Rate 2021-2032 (K Units)
- Figure 7. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth Rate 2021-2032 (\$ millions)
- Figure 8. Renin-Angiotensin-System (RAS)-Acting Agent Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Figure 9. Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Country/Region (2025)
- Figure 10. Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Country/Region (2021, 2025 & 2032)
- Figure 11. Product Picture of Angiotensin Converting Enzyme Inhibitors (ACEi)
- Figure 12. Product Picture of Angiotensin Receptor Blockers (ARBs)
- Figure 13. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Type in 2026
- Figure 14. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Type (2021-2026)
- Figure 15. Renin-Angiotensin-System (RAS)-Acting Agent Consumed in Hypertension
- Figure 16. Global Renin-Angiotensin-System (RAS)-Acting Agent Market: Hypertension (2021-2026) & (K Units)
- Figure 17. Renin-Angiotensin-System (RAS)-Acting Agent Consumed in Heart Failure
- Figure 18. Global Renin-Angiotensin-System (RAS)-Acting Agent Market: Heart Failure (2021-2026) & (K Units)
- Figure 19. Renin-Angiotensin-System (RAS)-Acting Agent Consumed in Chronic Kidney Disease
- Figure 20. Global Renin-Angiotensin-System (RAS)-Acting Agent Market: Chronic Kidney Disease (2021-2026) & (K Units)
- Figure 21. Renin-Angiotensin-System (RAS)-Acting Agent Consumed in Other
- Figure 22. Global Renin-Angiotensin-System (RAS)-Acting Agent Market: Other (2021-2026) & (K Units)
- Figure 23. Global Renin-Angiotensin-System (RAS)-Acting Agent Sale Market Share by

Application (2025)

Figure 24. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Application in 2026

Figure 25. Renin-Angiotensin-System (RAS)-Acting Agent Sales by Company in 2026 (K Units)

Figure 26. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Company in 2026

Figure 27. Renin-Angiotensin-System (RAS)-Acting Agent Revenue by Company in 2026 (\$ millions)

Figure 28. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Company in 2026

Figure 29. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Geographic Region (2021-2026)

Figure 30. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Geographic Region in 2026

Figure 31. Americas Renin-Angiotensin-System (RAS)-Acting Agent Sales 2021-2026 (K Units)

Figure 32. Americas Renin-Angiotensin-System (RAS)-Acting Agent Revenue 2021-2026 (\$ millions)

Figure 33. APAC Renin-Angiotensin-System (RAS)-Acting Agent Sales 2021-2026 (K Units)

Figure 34. APAC Renin-Angiotensin-System (RAS)-Acting Agent Revenue 2021-2026 (\$ millions)

Figure 35. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales 2021-2026 (K Units)

Figure 36. Europe Renin-Angiotensin-System (RAS)-Acting Agent Revenue 2021-2026 (\$ millions)

Figure 37. Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales 2021-2026 (K Units)

Figure 38. Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Revenue 2021-2026 (\$ millions)

Figure 39. Americas Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Country in 2026

Figure 40. Americas Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Country (2021-2026)

Figure 41. Americas Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Type (2021-2026)

Figure 42. Americas Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Application (2021-2026)

Figure 43. United States Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth 2021-2026 (\$ millions)

Figure 44. Canada Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth 2021-2026 (\$ millions)

Figure 45. Mexico Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth 2021-2026 (\$ millions)

Figure 46. Brazil Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth 2021-2026 (\$ millions)

Figure 47. APAC Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Region in 2026

Figure 48. APAC Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Region (2021-2026)

Figure 49. APAC Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Type (2021-2026)

Figure 50. APAC Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Application (2021-2026)

Figure 51. China Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth 2021-2026 (\$ millions)

Figure 52. Japan Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth 2021-2026 (\$ millions)

Figure 53. South Korea Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth 2021-2026 (\$ millions)

Figure 54. Southeast Asia Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth 2021-2026 (\$ millions)

Figure 55. India Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth 2021-2026 (\$ millions)

Figure 56. Australia Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth 2021-2026 (\$ millions)

Figure 57. China Taiwan Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth 2021-2026 (\$ millions)

Figure 58. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Country in 2026

Figure 59. Europe Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share by Country (2021-2026)

Figure 60. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Type (2021-2026)

Figure 61. Europe Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share by Application (2021-2026)

Figure 62. Germany Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth

2021-2026 (\$ millions)

Figure 63. France Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth
2021-2026 (\$ millions)

Figure 64. UK Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth
2021-2026 (\$ millions)

Figure 65. Italy Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth
2021-2026 (\$ millions)

Figure 66. Russia Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth
2021-2026 (\$ millions)

Figure 67. Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales
Market Share by Country (2021-2026)

Figure 68. Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales
Market Share by Type (2021-2026)

Figure 69. Middle East & Africa Renin-Angiotensin-System (RAS)-Acting Agent Sales
Market Share by Application (2021-2026)

Figure 70. Egypt Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth
2021-2026 (\$ millions)

Figure 71. South Africa Renin-Angiotensin-System (RAS)-Acting Agent Revenue
Growth 2021-2026 (\$ millions)

Figure 72. Israel Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth
2021-2026 (\$ millions)

Figure 73. Turkey Renin-Angiotensin-System (RAS)-Acting Agent Revenue Growth
2021-2026 (\$ millions)

Figure 74. GCC Countries Renin-Angiotensin-System (RAS)-Acting Agent Revenue
Growth 2021-2026 (\$ millions)

Figure 75. Manufacturing Cost Structure Analysis of Renin-Angiotensin-System
(RAS)-Acting Agent in 2026

Figure 76. Manufacturing Process Analysis of Renin-Angiotensin-System (RAS)-Acting
Agent

Figure 77. Industry Chain Structure of Renin-Angiotensin-System (RAS)-Acting Agent

Figure 78. Channels of Distribution

Figure 79. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market
Forecast by Region (2027-2032)

Figure 80. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market
Share Forecast by Region (2027-2032)

Figure 81. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share
Forecast by Type (2027-2032)

Figure 82. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market
Share Forecast by Type (2027-2032)

Figure 83. Global Renin-Angiotensin-System (RAS)-Acting Agent Sales Market Share Forecast by Application (2027-2032)

Figure 84. Global Renin-Angiotensin-System (RAS)-Acting Agent Revenue Market Share Forecast by Application (2027-2032)

I would like to order

Product name: Global Renin-Angiotensin-System (RAS)-Acting Agent Market Growth 2026-2032

Product link: <https://marketpublishers.com/r/G5876E99CAE5EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G5876E99CAE5EN.html>